Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab + Lenvatinib + SOX in Advanced Gastric/GEJ Cancer
NCT07356466Phase 1Enrolling by invitation
- Sponsor
- Fujian Medical University
- Start
- May 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial of pucotenlimab and lenvatinib in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Fujian Medical University. Primary endpoint: Objective Response Rate at 30 days. Started May 2025; status: enrolling by invitation.
02
Drugs
pucotenlimablenvatinib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07356466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07356466.